Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors (nonresectable or metastatic) or enhancing gliomas.

hormonal oral contraceptives
renal function
bilateral tubal ligation
neutrophil count
measurable disease
  • 0 views
  • 13 Jun, 2021
  • 1 location
AG-120 in People With IDH1 Mutant Chondrosarcoma

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

cancer
kidney function tests
neutrophil count
measurable disease
  • 5 views
  • 12 May, 2022
  • 1 location
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)

azacitidine
blast cells
cytopenia
blood transfusion
bone marrow procedure
  • 7 views
  • 14 Feb, 2022
  • 2 locations
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an

cancer
bone marrow procedure
hematologic malignancy
  • 6 views
  • 27 May, 2022
  • 14 locations
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes …

total body irradiation
antibody therapy
metastasis
bone marrow procedure
nervous system disorder
  • 395 views
  • 29 Jun, 2022
  • 91 locations